

DAFTAR PUSTAKA

- Al-Badr, W. and Martin, K. J. (2008) 'Vitamin D and kidney disease', *Clinical Journal of the American Society of Nephrology*, 3(5), pp. 1555–1560. doi: 10.2215/CJN.01150308.
- Altemose, K. E. et al. (2018) 'Vitamin D insufficiency, hemoglobin, and anemia in children with chronic kidney disease', *Pediatric Nephrology*, 33(11), pp. 2131–2136. doi: 10.1007/s00467-018-4020-5.
- Alvarez, J. A. et al. (2012) 'High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: A pilot, randomized, double-blind, placebo-controlled trial', *American Journal of Clinical Nutrition*, 96(3), pp. 672–679. doi: 10.3945/ajcn.112.040642.
- Alvarez, J. A. et al. (2013) 'Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease', *European Journal of Clinical Nutrition*, 67(3), pp. 264–269. doi: 10.1038/ejcn.2012.217.
- Andress, D. L. (2006) 'Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation', *Kidney International*, 69(1), pp. 33–43. doi: 10.1038/sj.ki.5000045.
- Atkinson, M. A. et al. (2010) 'Risk for anemia in pediatric chronic kidney disease patients: A report of NAPRTCS', *Pediatric Nephrology*, 25(9), pp. 1699–1706. doi: 10.1007/s00467-010-1538-6.
- Atkinson, M. A. et al. (2014) 'Vitamin D, race, and risk for anemia in children', *Journal of Pediatrics*, 164(1). doi: 10.1016/j.jpeds.2013.08.060.
- Atkinson, M. A. et al. (2015) 'Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort', *Pediatric Nephrology*, 30(4), pp. 635–643. doi: 10.1007/s00467-014-2991-4.
- Bacchetta, J. et al. (2014) 'Suppression of iron-regulatory hepcidin by vitamin D', *Journal of the American Society of Nephrology*, 25(3), pp.

- 564–572. doi: 10.1681/ASN.2013040355.
- Bamgbola, O. F. (2011) ‘Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease’, *Kidney International*. Nature Publishing Group, pp. 464–474. doi: 10.1038/ki.2011.179.
- Becherucci, F. et al. (2016) ‘Chronic kidney disease in children’, *Clinical Kidney Journal*, 9(4), pp. 583–591. doi: 10.1093/ckj/sfw047.
- Bek, S. G. et al. (2020) ‘The effect of hepcidin on components of metabolic syndrome in chronic kidney disease: A cross-sectional study’, *Revista da Associacao Medica Brasileira*, 66(8), pp. 1100–1107. doi: 10.1590/1806-9282.66.8.1100.
- Bell (2013) ‘The Effect of Vitamin D3 on Hepcidin and IL-8 Expression in Monocytes’, *Journal of Hematology*. doi: 10.4021/jh71e.
- Bhimma, R. et al. (2008) ‘The spectrum of chronic kidney disease (stages 2-5) in KwaZulu-Natal, South Africa’, *Pediatric Nephrology*, 23(10), pp. 1841–1846. doi: 10.1007/s00467-008-0871-5.
- Biljak, V. R. et al. (2017) ‘The role of laboratory testing in detection and classification of chronic kidney disease: national recommendations’, *Biochimia Medica*, 27(1), pp. 153–176.
- Van Biljon, I. and Meyers, A. M. (2015) ‘Paediatric chronic kidney disease’, *South African Medical Journal*, 105(4), pp. 316–319. doi: 10.7196/SAMJ.9532.
- Canova, S., Cortinovis, D. L. and Ambrogi, F. (2017) ‘How to describe univariate data’, *Journal of Thoracic Disease*, 9(6), pp. 1741–1743. doi: 10.21037/jtd.2017.05.80.
- Carmody, J. B. and Charlton, J. R. (2013) ‘Short-term gestation, long-term risk: Prematurity and chronic kidney disease’, *Pediatrics*. American Academy of Pediatrics, pp. 1168–1179. doi: 10.1542/peds.2013-0009.
- Carvalho, C. et al. (2011) ‘Hepcidin and disordered mineral metabolism in chronic kidney disease’, *Clinical Nephrology*, 76(2), pp. 90–98. doi: 10.5414/cn107018.

- Chang, S. W. and Lee, H. C. (2019) 'Vitamin D and health - The missing vitamin in humans', *Pediatrics and Neonatology*, 60(3), pp. 237–244. doi: 10.1016/j.pedneo.2019.04.007.
- Chou, H. H. et al. (2016) 'Clinical characteristics and prevalence of complications of chronic kidney disease in children: the Taiwan Pediatric Renal Collaborative study', *Pediatric Nephrology*, 31(7), pp. 1113–1120. doi: 10.1007/s00467-016-3325-5.
- Dewan, P. et al. (2019) 'Serum and Urinary Hepcidin for Diagnosing Iron-deficiency Anemia in Under-5 Children', *Journal of Pediatric Hematology/Oncology*, 41(4), pp. e216–e220. doi: 10.1097/MPH.0000000000001320.
- Fakhoury, M., Levy, R. and Melamed, M. L. (2019) 'Vitamin D deficiency and kidney hyperfiltration: a mechanism of kidney injury?', *Annals of Translational Medicine*, 7(S6), pp. S207–S207. doi: 10.21037/atm.2019.06.64.
- Fraser, S. D. and Blakeman, T. (2018) 'Chronic kidney disease: identification and management in primary care', *Pragmatic and Observational Research*, (7), pp. 21–32. doi: 10.3122/jabfm.2010.04.090129.
- Gafter-Gvili, A., Schechter, A. and Rozen-Zvi, B. (2019) 'Iron Deficiency Anemia in Chronic Kidney Disease', *Acta Haematologica*, 142(1), pp. 44–50. doi: 10.1159/000496492.
- Ganz, T. et al. (2008) 'Immunoassay for human serum hepcidin', *Blood*, 112(10), pp. 4292–4297. doi: 10.1182/blood-2008-02-139915.
- Ganz, T. (2011) 'Hepcidin and iron regulation, 10 years later', *Blood*. American Society of Hematology, pp. 4425–4433. doi: 10.1182/blood-2011-01-258467.
- Ganz, T. and Nemeth, E. (2016) 'Iron Balance and the Role of Hepcidin in Chronic Kidney Disease', *Seminars in Nephrology*, 36(2), pp. 87–93. doi: 10.1016/j.semnephrol.2016.02.001.
- Gaweda, A. E. et al. (2010) 'Iron, inflammation, dialysis adequacy,

- nutritional status, and hyperparathyroidism modify erythropoietic response', *Clinical Journal of the American Society of Nephrology*, 5(4), pp. 576–581. doi: 10.2215/CJN.04710709.
- Gil, Á., Plaza-Diaz, J. and Mesa, M. D. (2018) 'Vitamin D: Classic and Novel Actions', *Annals of Nutrition and Metabolism*, 72(2), pp. 87–95. doi: 10.1159/000486536.
- Girelli, D., Nemeth, E. and Swinkels, D. W. (2016) 'Blood Spotlight Hepcidin in the diagnosis of iron disorders', *Blood*, 127(23), pp. 2809–2814. doi: 10.1182/blood-2015-12-639112.The.
- Gois, P. H. F. et al. (2018) 'Vitamin D deficiency in chronic kidney disease: Recent evidence and controversies', *International Journal of Environmental Research and Public Health*, 15(8), pp. 1–16. doi: 10.3390/ijerph15081773.
- Harambat, J. et al. (2012) 'Epidemiology of chronic kidney disease in children', *Pediatric Nephrology*. Springer Verlag, pp. 363–373. doi: 10.1007/s00467-011-1939-1.
- Hidayati, E. L. and Trihono, P. P. (2011) 'Admission characteristics of pediatric chronic kidney disease', *Paediatrica Indonesiana*, 51(4), p. 192. doi: 10.14238/pi51.4.2011.192-7.
- Indah Lestari, H. et al. (2020) *Kelainan Mineral Tulang pada Anak dengan Penyakit Ginjal Kronik*, Sari Pediatri. Available at: <https://saripediatri.org/index.php/sari-pediatri/article/view/1589> (Accessed: 21 July 2020).
- Jean, G., Souberbielle, J. C. and Chazot, C. (2017) 'Vitamin D in chronic kidney disease and dialysis patients', *Nutrients*, 9(4), pp. 1–15. doi: 10.3390/nut9040328.
- Kaspar, C. D. W., Bholah, R. and Bunchman, T. E. (2016) 'A Review of Pediatric Chronic Kidney Disease', *Blood Purification*, 41(1–3), pp. 211–217. doi: 10.1159/000441737.
- Kong, F. et al. (2019) 'Decreased 25-Hydroxyvitamin D Level Is Linked to Anemia in Peritoneal Dialysis Patients', *Archives of Clinical and*

- Biomedical Research*, 3(2), pp. 36–046. doi: 10.26502/acbr.50170066.
- kotb abdellatif, A. et al. (2015) *Effect of vitamin D on Hepcidin Level and anemia in chronic kidney Disease*, *Life Science Journal*. Available at: <http://www.lifesciencesite.comhttp://www.lifesciencesite.com.20> (Accessed: 22 May 2021).
- Kumar, J. et al. (2016) ‘Prevalence and correlates of 25-hydroxyvitamin D deficiency in the Chronic Kidney Disease in Children (CKD) cohort’, *Pediatric Nephrology*, 31(1), pp. 121–129. doi: 10.1007/s00467-015-3190-7.
- LaClair, R. E. et al. (2005) ‘Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States’, *American Journal of Kidney Diseases*, 45(6), pp. 1026–1033. doi: 10.1053/j.ajkd.2005.02.029.
- Lestari, H. I. (2020) *The Role of Vitamin D and Hepcidin in Pathophysiology of Anaemia in Children with Chronic Kidney Disease*, *Sriwijaya Journal of Medicine*. Fakultas Kedokteran Universitas Sriwijaya. Available at: <https://www.jurnalkedokteranunsri.id/index.php/UnsriMedJ/article/view/109> (Accessed: 23 May 2021).
- Moran-Lev, H. et al. (2018) ‘The interrelationship between hepcidin, vitamin D, and anemia in children with acute infectious disease’, *Pediatric Research*, 84(1), pp. 62–65. doi: 10.1038/s41390-018-0005-0.
- Nayak, A. and Khare, J. (2017) ‘Pediatric Chronic Kidney Disease – A Child is Not a Young Adult’, *J Pedia Health Care Med*, 1(1), pp. 16–19.
- Nemeth, E. et al. (2004) ‘IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin’, *Journal of Clinical Investigation*, 113(9), pp. 1271–1276. doi: 10.1172/jci20945.

- North American Pediatric Renal Trials and and Collaborative Studies, N. (2011) 2011 Annual Dialysis Report. Available at: https://naprtcs.org/system/files/2011_Annual_Dialysis_Report.pdf (Accessed: 30 May 2021).
- Pamela Blazquez, J. (2017) 'High prevalence of vitamin D deficiency among children with chronic kidney disease and kidney transplant', *Arch Argent Pediatr*, 115(3), pp. 220–226. doi: 10.5546/aap.2017.eng.220.
- Panwar, B. et al. (2018) 'Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: A randomized controlled trial', *BMC Nephrology*, 19(1), p. 35. doi: 10.1186/s12882-018-0823-7.
- Pardede, S. O. and Chunnaedy, S. (2016) 'Penyakit Ginjal Kronik pada Anak', *Sari Pediatri*, 11(3), p. 199. doi: 10.14238/sp11.3.2009.199-206.
- Park, K. et al. (2009) 'Household food insecurity is a risk factor for iron-deficiency anaemia in a multi-ethnic, low-income sample of infants and toddlers', *Public Health Nutrition*, 12(11), pp. 2120–2128. doi: 10.1017/S1368980009005540.
- Peco-Antic, A. et al. (2012) 'Epidemiology of chronic kidney disease in children in Serbia.', *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*, 27(5), pp. 1978–1984. doi: 10.1093/ndt/gfr556.
- Peters, H. P. E. et al. (2010) 'Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate', *Nephrology Dialysis Transplantation*, 25(3), pp. 848–853. doi: 10.1093/ndt/gfp546.
- Pirojsakul, K., Mathews, N. and Seikaly, M. G. (2015) 'Chronic kidney disease in Children: Recent Update', *The Open Urology & Nephrology Journal*, 8, pp. 117–123. doi: 10.1542/pir.29-10-335.

- Pirojsakul, K., Mathews, N. and Seikaly, M. G. (2019) 'Chronic Kidney Disease in Children: Recent Update', *The Open Urology & Nephrology Journal*, 8(1), pp. 117–123. doi: 10.2174/1874303x015080100117.
- Rebholz, C. M. et al. (2016) 'Biomarkers of Vitamin D Status and Risk of ESRD', *Am J Kidney Dis*, 62(2), pp. 235–242. doi: 10.1016/j.physbeh.2017.03.040.
- RI KEMENKES (2018) *Laporan Hasil Riset Kesehatan Dasar (Riskesdas) / Badan Penelitian dan Pengembangan Kesehatan*. Available at: <https://www.litbang.kemkes.go.id/laporan-riset-kesehatan-dasar-riskesdas/> (Accessed: 21 July 2020).
- Rianthavorn, P. and Boonyapapong, P. (2013) 'Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5', *Pediatric Nephrology*, 28(8), pp. 1261–1266. doi: 10.1007/s00467-013-2431-x.
- Salem, A. A. (2015) 'Effect of vitamin D on Hepcidin Level and anemia in chronic kidney Disease', *Life Science Journal*, 12(6), pp. 155–160.
- Saneela, S. et al. (2019) 'Hepcidin, a key regulator of iron metabolism', *J Pak Med Assoc*, 69(8), pp. 1170–1174.
- Santos-Silva, A. et al. (2019) *Hepcidin in chronic kidney disease anemia*. 1st edn, *Vitamins and Hormones*. 1st edn. Elsevier Inc. doi: 10.1016/bs.vh.2019.01.012.
- Seeherunvong, W. et al. (2009) 'Vitamin D Insufficiency and Deficiency in Children with Early Chronic Kidney Disease', *Journal of Pediatrics*, 154(6), pp. 906-911.e1. doi: 10.1016/j.jpeds.2008.12.006.
- Shroff, R. et al. (2017) 'Clinical practice recommendations for native Vitamin D therapy in children with chronic kidney disease Stages 2-5 and on dialysis', *Nephrology Dialysis Transplantation*, 32(7), pp. 1098–1113. doi: 10.1093/ndt/gfx065.
- Smith, E. M. et al. (2017) 'High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-

- controlled trial in healthy adults', *Clinical Nutrition*, 36(4), pp. 980–985. doi: 10.1016/j.clnu.2016.06.015.
- Smith, E. M. and Tangpricha, V. (2015) 'Vitamin D and anemia: Insights into an emerging association', *Current Opinion in Endocrinology, Diabetes and Obesity*, 22(6), pp. 432–438. doi: 10.1097/MED.0000000000000199.
- Sun, C. C. et al. (2013) 'A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats', *Nephrology Dialysis Transplantation*, 28(7), pp. 1733–1743. doi: 10.1093/ndt/gfs584.
- Teumer, A. et al. (2018) 'Negative effect of Vitamin D on kidney function: A Mendelian randomization study', *Nephrology Dialysis Transplantation*, 33(12), pp. 2139–2145. doi: 10.1093/ndt/gfy074.
- Tsampalieros, A. et al. (2013) 'Changes in bone structure and the muscle-bone unit in children with chronic kidney disease', *Kidney International*, 83, pp. 495–502. doi: 10.1038/ki.2012.347.
- Ueda, N. and Takasawa, K. (2018) 'Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease', *Nutrients*, 10(9). doi: 10.3390/nu10091173.
- Valenti, L. et al. (2011) 'Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations', *Arteriosclerosis, Thrombosis, and Vascular Biology*, 31(3), pp. 683–690. doi: 10.1161/ATVBAHA.110.214858.
- Wang, Y. et al. (2019) 'Effects of Vitamin D supplementation on renal function, inflammation and glycemic control in patients with diabetic nephropathy: A systematic review and meta-analysis', *Kidney and Blood Pressure Research*, 44(1), pp. 72–87. doi: 10.1159/000498838.
- Whyte, D. A. and Fine, R. N. (2008) 'Chronic kidney disease in children', *Pediatrics in Review*, 29(10), pp. 335–341.

- Xiao, N. *et al.* (2014) 'Kidney function in severely obese adolescents undergoing bariatric surgery', *Obesity*, 22(11), pp. 2319–2325. doi: 10.1002/oby.20870.
- Yeşilbaş, O. *et al.* (2019) 'Is hepcidin related with anemia and bone mineral metabolism in children with non-dialysis chronic kidney disease?', *Turk Pediatri Arsivi*, 54(4), pp. 238–245. doi: 10.14744/TurkPediatriArs.2019.93206.
- Yoo, E. H. and Cho, H. J. (2015) 'Prevalence of 25-Hydroxyvitamin D deficiency in korean patients with anemia', *Journal of Clinical Laboratory Analysis*, 29(2), pp. 129–134. doi: 10.1002/jcla.21740.
- Zughaiier, S. M. *et al.* (2014a) 'The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes', *Journal of Clinical and Translational Endocrinology*, 1(1), pp. e19–e25. doi: 10.1016/j.jcte.2014.01.003.
- Zughaiier, S. M. *et al.* (2014b) 'The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes', *Journal of Clinical and Translational Endocrinology*, 1(1). doi: 10.1016/j.jcte.2014.01.003.

LAMPIRAN 1

NASKAH PENJELASAN UNTUK MENDAPATKAN PERSETUJUAN DARI SUBJEK PENELITIAN (INFORMASI UNTUK SUBJEK)

HUBUNGAN ANTARA KADAR VITAMIN D DAN HEPCIDIN SERUM PENYAKIT GINJAL KRONIK PADA ANAK

Assalamu'alaikum /Selamat pagi ibu/bapak, saya dr. Lingga Pradipta, residen dari Departemen Ilmu Kesehatan Anak RS Dr. Wahidin Sudirohusodo, yang akan melayani ibu/bapak.

Saya akan memaparkan sedikit mengenai penyakit ginjal kronik merupakan masalah kesehatan pada anak yang cukup serius dengan prevalensi dan mortalitas yang semakin meningkat dari tahun ke tahun. Penyakit ginjal kronik menjadi masalah kesehatan utama yang dihadapi seluruh dunia dengan angka prevalensi dan insidensi yang juga semakin tinggi, diperkirakan kejadian penyakit ginjal kronik lebih tinggi dari data yang ada karena banyak kasus yang tidak terdeteksi.

Kejadian penyakit ginjal kronik di setiap negara berbeda. Di Indonesia sendiri, belum ada data nasional tentang kejadian penyakit ginjal kronik. Kualitas hidup anak dengan penyakit ginjal kronik lebih rendah dibandingkan anak sehat, baik secara fisik, emosional, sosial, maupun prestasi belajar. Penderita penyakit ginjal kronik berisiko untuk mengalami kelainan mineral saat terjadi penurunan fungsi ginjal. Kekurangan vitamin D dan peningkatan hormone hepcidin sering ditemukan pada anak penyakit ginjal kronik usia <21 tahun.

Penelitian ini tidak dilakukan intervensi pemberian suplementasi vitamin D namun penelitian ini mengukur kadar vitamin D dan Hepcidin serum pada anak dengan penyakit ginjal kronik.

Penelitian ini juga kedepannya dapat menjadi dasar dalam menentukan target terapi dalam penanganan penyakit ginjal kronik yang secara umum diharapkan pasien akan lebih mudah mencapai kesembuhan termasuk untuk seluruh subyek pada penelitian ini.

Pemeriksaan kadar vitamin D dan Hepcidin serum pada penelitian ini dilakukan melalui pemeriksaan darah. Anak akan diambil darahnya sebanyak 5 cc kemudian darah tersebut dimasukkan ke dalam tabung bertutup merah. Akan tetapi dalam pengambilan darah dapat terjadi hal-hal yang tidak dikenakan atau mengganggu anak. Hal-hal tersebut misalnya rasa tidak nyaman ataupun rasa nyeri pada saat pengambilan sampel dan rasa takut karena akan ditusuk dengan jarum, oleh karena itu pengambilan sampel akan dilakukan oleh orang yang ahli dan berpengalaman. Apabila Ibu/ Bapak menyetujui anaknya diikutkan dalam penelitian ini, Ibu/ Bapak dipersilahkan menandatangani lembar persetujuan penelitian yang sudah dipersiapkan.

Keikutsertaan anak Ibu/ Bapak dalam penelitian ini bersifat sukarela tanpa paksaan dan dalam keikutsertaan tersebut tidak diberikan kompensasi materi. Ibu/ Bapak bisa menolak ikut atau berhenti tanpa takut akan kehilangan hak untuk mendapat pelayanan kesehatan yang dibutuhkan oleh anak ibu/ Bapak. Bila Ibu/ Bapak setuju berpartisipasi dalam penelitian ini, maka diharapkan dapat menandatangani formulir persetujuan (terlampir). Untuk mengetahui secara mendetail mengenai penelitian ini atau ada hal-hal yang belum jelas, dapat menghubungi saya dengan nomor telepon 082135221472.

Semua data dari penelitian ini akan dicatat dan dipublikasikan tanpa membuka data pribadi anak Ibu/ Bapak. Data pada penelitian ini akan dikumpulkan dan disimpan dalam file manual maupun elektronik, diaudit dan diproses serta dipresentasikan pada :

- Forum Ilmiah Program Pendidikan Dokter Spesialis Anak FK-UNHAS
- Publikasi pada jurnal ilmiah dalam maupun luar negeri

Setelah membaca dan mengerti penjelasan yang kami berikan,besar harapan kami Ibu/ Bapak bersedia berpartisipasi dalam penelitian ini. Atas waktu dan kerjasamanya kami mengucapkan terima kasih.
Wassalam.

Penanggung Jawab Penelitian :

Nama : Lingga Pradipta
Alamat : Jalan poros Wesabbe no. C65, Kecamatan Tamalanrea, Kota Makassar, Sulawesi Selatan
Telepon : 082135221472

Penanggung Jawab Medis :

Nama : dr. Jusli Aras, M. Kes, Sp.A(K)
Alamat : Jalan Boulevard Kompleks Tulip No. C1-31, Kecamatan Panakukang, Kota Makassar
Telepon : 08114517576

**DISETUJUI OLEH
KOMISI ETIK PENELITIAN
KESEHATAN
FAK. KEDOKTERAN UNHAS
Tgl.....**

Lampiran 2

FORMULIR PERSETUJUAN ORANG TUA MENGIKUTI PENELITIAN SETELAH MENDAPAT PENJELASAN

Maka saya yang bertanda tangan di bawah ini, orang tua/ wali :

Nama :

Pekerjaan :

Alamat :

Setelah mendengar dan mengerti penjelasan yang diberikan oleh dr. Lingga Pradipta tentang penelitian yang akan dilakukannya, bersama ini secara sukarela mengizinkan anak saya :

Nama :

Jenis kelamin : Laki-laki / Perempuan

untuk diikutkan dalam penelitian ini.

Saya tahu bahwa saya mempunyai hak untuk menanyakan pada dr. Lingga Pradipta apabila masih ada hal-hal yang belum jelas. Saya juga tahu bahwa saya tidak perlu merasa terpaksa mengikutkan anak saya dalam penelitian ini.

Saya juga mengerti bahwa saya tidak perlu membayar semua biaya pemeriksaan yang ada hubungannya dengan penelitian ini, dan semua biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak diinginkan akan dibiayai oleh peneliti, jika terjadi perselisihan/beda pendapat akan diselesaikan secara musyawarah (kekeluargaan).

Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Makassar,.....

| NO. | NAMA | TANDA TANGAN |
|-------------------|-------|--------------|
| 1. ORANG TUA/WALI | | |
| 2. SAKSI I | | |
| 3. SAKSI II | | |

Penanggung Jawab Penelitian :

Nama : dr. Lingga Pradipta
Alamat : Jl. Poros Wesabbe
No.C65, Tamalanrea,
Kec. Tamalanrea, Kota
Makassar
Telepon : 082135221472

Penanggung Jawab Medis :

Nama : dr. Jusli, Mkes, Sp. A(K)
Alamat : Jl. Boulevard komplek tulip No. C1-31
Telepon : 08114517576



REKOMENDASI PERSETUJUAN ETIK

Nomor: 340/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 25 Mei 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik:

| | | | |
|--|---|--|------------------------------|
| No Protokol | UH21040251 | No Sponsor Protokol | |
| Peneliti Utama | dr. Lingga Pradipta | Sponsor | |
| Judul Peneliti | HUBUNGAN ANTARA KADAR VITAMIN D DAN HEPcidin SERUM PENYAKIT GINJAL KRONIK PADA ANAK | | |
| No Versi Protokol | 2 | Tanggal Versi | 21 Mei 2021 |
| No Versi PSP | 2 | Tanggal Versi | 21 Mei 2021 |
| Tempat Penelitian | RS Universitas Hasanuddin dan RS Dr. Wahidin Sudirohusodo Makassar | | |
| Jenis Review | <input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 5 Mei 2021 | Masa Berlaku 25 Mei 2021 sampai 25 Mei 2022 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH | Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K) | Tanda tangan | |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K) | Tanda tangan | |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

1. Lampiran Karakteristik dan Distribusi Sampel

Frequency Table

| Grade | | | | | |
|-------|-----------|---------|---------------|--------------------|-------|
| | Frequency | Percent | Valid Percent | Cumulative Percent | |
| Valid | 1.00 | 20 | 50.0 | 50.0 | 50.0 |
| | 2.00 | 4 | 10.0 | 10.0 | 60.0 |
| | 3.00 | 2 | 5.0 | 5.0 | 65.0 |
| | 4.00 | 1 | 2.5 | 2.5 | 67.5 |
| | 5.00 | 2 | 5.0 | 5.0 | 72.5 |
| | 6.00 | 11 | 27.5 | 27.5 | 100.0 |
| Total | | 40 | 100.0 | 100.0 | |

| Jenis Kelamin | | | | | |
|---------------|-----------|---------|---------------|--------------------|-------|
| | Frequency | Percent | Valid Percent | Cumulative Percent | |
| Valid | 1.00 | 20 | 50.0 | 50.0 | 50.0 |
| | 2.00 | 20 | 50.0 | 50.0 | 100.0 |
| | Total | 40 | 100.0 | 100.0 | |

| Usia | | | | | |
|-------|-----------|---------|---------------|--------------------|-------|
| | Frequency | Percent | Valid Percent | Cumulative Percent | |
| Valid | 1.00 | 7 | 17.5 | 17.5 | 17.5 |
| | 2.00 | 14 | 35.0 | 35.0 | 52.5 |
| | 3.00 | 19 | 47.5 | 47.5 | 100.0 |
| | Total | 40 | 100.0 | 100.0 | |

| Status Gizi | | | | | |
|-------------|-----------|---------|---------------|--------------------|-------|
| | Frequency | Percent | Valid Percent | Cumulative Percent | |
| Valid | 1.00 | 7 | 17.5 | 17.5 | 17.5 |
| | 2.00 | 25 | 62.5 | 62.5 | 80.0 |
| | 3.00 | 5 | 12.5 | 12.5 | 92.5 |
| | 4.00 | 3 | 7.5 | 7.5 | 100.0 |
| | Total | 40 | 100.0 | 100.0 | |

| Vit D | | | | | |
|-------|-----------|---------|---------------|--------------------|-------|
| | Frequency | Percent | Valid Percent | Cumulative Percent | |
| Valid | 1.00 | 28 | 70.0 | 70.0 | 70.0 |
| | 2.00 | 5 | 12.5 | 12.5 | 82.5 |
| | 3.00 | 7 | 17.5 | 17.5 | 100.0 |
| | Total | 40 | 100.0 | 100.0 | |

| Statistics | | | | | | |
|----------------|---------|----------|----------|----------|----------|----------|
| | hep2 | vitd | GFRNEW | Usia | BB | TB |
| N | Valid | 40 | 40 | 40 | 40 | 40 |
| | Missing | 0 | 0 | 0 | 0 | 0 |
| Mean | 26.5925 | 20.6915 | 94.4650 | 129.6750 | 29.8400 | 128.5500 |
| Median | 26.3000 | 15.6500 | 85.2000 | 136.5000 | 29.5000 | 131.0000 |
| Std. Deviation | 4.80125 | 13.06238 | 85.87699 | 63.26111 | 13.79940 | 27.06114 |
| Minimum | 15.80 | 5.26 | 3.00 | 7.00 | 7.20 | 65.00 |
| Maximum | 36.30 | 65.10 | 374.00 | 215.00 | 61.00 | 171.00 |

2. Perbandingan Kadar Hepcidin, Vitamin D, dan GFR berdasarkan Usia pada anak dengan PGK

Descriptives

| | | Usia_cat | Statistic | Std. Error |
|--------|------|----------------------------------|-------------|-------------|
| hep2 | 1.00 | Mean | 27.5857 | 1.69880 |
| | | 95% Confidence Interval for Mean | Lower Bound | 23.4289 |
| | | | Upper Bound | 31.7425 |
| | | 5% Trimmed Mean | | 27.5952 |
| | | Median | | 27.6000 |
| | | Variance | | 20.201 |
| | | Std. Deviation | | 4.49460 |
| | | Minimum | | 20.80 |
| | | Maximum | | 34.20 |
| | | Range | | 13.40 |
| | | Interquartile Range | | 7.00 |
| | | Skewness | | -.067 .794 |
| | | Kurtosis | | -.414 1.587 |
| 2.00 | 2.00 | Mean | 27.3214 | 1.32624 |
| | | 95% Confidence Interval for Mean | Lower Bound | 24.4563 |
| | | | Upper Bound | 30.1866 |
| | | 5% Trimmed Mean | | 27.3127 |
| | | Median | | 27.6000 |
| | | Variance | | 24.625 |
| | | Std. Deviation | | 4.96235 |
| | | Minimum | | 18.50 |
| | | Maximum | | 36.30 |
| | | Range | | 17.80 |
| | | Interquartile Range | | 7.93 |
| | | Skewness | | .019 .597 |
| | | Kurtosis | | -.570 1.154 |
| 3.00 | 3.00 | Mean | 25.6895 | 1.11850 |
| | | 95% Confidence Interval for Mean | Lower Bound | 23.3396 |
| | | | Upper Bound | 28.0394 |
| | | 5% Trimmed Mean | | 25.6661 |
| | | Median | | 25.8000 |
| | | Variance | | 23.770 |
| | | Std. Deviation | | 4.87544 |
| | | Minimum | | 15.80 |
| | | Maximum | | 36.00 |
| | | Range | | 20.20 |
| | | Interquartile Range | | 5.40 |
| | | Skewness | | .161 .524 |
| | | Kurtosis | | .260 1.014 |
| GFRNEW | 1.00 | Mean | 78.8571 | 28.99707 |
| | | 95% Confidence Interval for | Lower Bound | 7.9039 |

| | | | | | |
|------|------|----------------------------------|-------------|----------|----------|
| | | Mean | Upper Bound | 149.8104 | |
| | | 5% Trimmed Mean | | 77.3968 | |
| | | Median | | 71.0000 | |
| | | Variance | | 5885.810 | |
| | | Std. Deviation | | 76.71903 | |
| | | Minimum | | 6.00 | |
| | | Maximum | | 178.00 | |
| | | Range | | 172.00 | |
| | | Interquartile Range | | 169.00 | |
| | | Skewness | | .439 | .794 |
| | | Kurtosis | | -1.804 | 1.587 |
| 2.00 | | Mean | | 101.4500 | 23.31296 |
| | | 95% Confidence Interval for Mean | Lower Bound | 51.0854 | |
| | | | Upper Bound | 151.8146 | |
| | | 5% Trimmed Mean | | 96.5556 | |
| | | Median | | 100.8500 | |
| | | Variance | | 7608.918 | |
| | | Std. Deviation | | 87.22911 | |
| | | Minimum | | 3.00 | |
| | | Maximum | | 288.00 | |
| | | Range | | 285.00 | |
| | | Interquartile Range | | 131.55 | |
| | | Skewness | | .726 | .597 |
| | | Kurtosis | | .013 | 1.154 |
| 3.00 | | Mean | | 95.0684 | 21.01193 |
| | | 95% Confidence Interval for Mean | Lower Bound | 50.9240 | |
| | | | Upper Bound | 139.2128 | |
| | | 5% Trimmed Mean | | 84.6871 | |
| | | Median | | 77.0000 | |
| | | Variance | | 8388.522 | |
| | | Std. Deviation | | 91.58888 | |
| | | Minimum | | 3.00 | |
| | | Maximum | | 374.00 | |
| | | Range | | 371.00 | |
| | | Interquartile Range | | 132.80 | |
| | | Skewness | | 1.563 | .524 |
| | | Kurtosis | | 3.643 | 1.014 |
| vitd | 1.00 | Mean | | 18.5571 | 2.60685 |
| | | 95% Confidence Interval for Mean | Lower Bound | 12.1784 | |
| | | | Upper Bound | 24.9359 | |
| | | 5% Trimmed Mean | | 18.1635 | |
| | | Median | | 17.3000 | |
| | | Variance | | 47.570 | |
| | | Std. Deviation | | 6.89707 | |
| | | Minimum | | 11.70 | |

| | | | |
|------|----------------------------------|-------------|---------|
| | Maximum | 32.50 | |
| | Range | 20.80 | |
| | Interquartile Range | 7.20 | |
| | Skewness | 1.583 | .794 |
| | Kurtosis | 3.019 | 1.587 |
| 2.00 | Mean | 21.4786 | 3.99138 |
| | 95% Confidence Interval for Mean | Lower Bound | 12.8557 |
| | | Upper Bound | 30.1014 |
| | 5% Trimmed Mean | 20.1706 | |
| | Median | 17.0000 | |
| | Variance | 223.036 | |
| | Std. Deviation | 14.93438 | |
| | Minimum | 6.50 | |
| | Maximum | 60.00 | |
| | Range | 53.50 | |
| | Interquartile Range | 14.10 | |
| | Skewness | 1.618 | .597 |
| | Kurtosis | 2.392 | 1.154 |
| 3.00 | Mean | 20.8979 | 3.16604 |
| | 95% Confidence Interval for Mean | Lower Bound | 14.2463 |
| | | Upper Bound | 27.5495 |
| | 5% Trimmed Mean | 19.3110 | |
| | Median | 15.0000 | |
| | Variance | 190.453 | |
| | Std. Deviation | 13.80046 | |
| | Minimum | 5.26 | |
| | Maximum | 65.10 | |
| | Range | 59.84 | |
| | Interquartile Range | 8.10 | |
| | Skewness | 2.185 | .524 |
| | Kurtosis | 5.333 | 1.014 |

Tests of Normality

| Usia_cat | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
|----------|---------------------------------|------|------|--------------|----|-------|
| | Statistic | df | Sig. | Statistic | df | Sig. |
| hep2 | 1.00 | .102 | .200 | .997 | 7 | 1.000 |
| | 2.00 | .099 | .200 | .985 | 14 | .995 |
| | 3.00 | .109 | .200 | .985 | 19 | .984 |
| GFRNEW | 1.00 | .247 | .200 | .834 | 7 | .088 |
| | 2.00 | .130 | .200 | .924 | 14 | .250 |
| | 3.00 | .157 | .200 | .846 | 19 | .006 |
| vitd | 1.00 | .235 | .200 | .864 | 7 | .166 |
| | 2.00 | .275 | .005 | .813 | 14 | .007 |
| | 3.00 | .263 | .001 | .736 | 19 | .000 |

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Oneway

Descriptives

hep2

| | N | Mean | Std. Deviation | Std. Error | 95% Confidence Interval for Mean | | |
|-------|----|---------|----------------|------------|----------------------------------|-------------|---------|
| | | | | | Lower Bound | Upper Bound | Minimum |
| 1.00 | 7 | 27.5857 | 4.49460 | 1.69880 | 23.4289 | 31.7425 | 20.80 |
| 2.00 | 14 | 27.3214 | 4.96235 | 1.32624 | 24.4563 | 30.1866 | 18.50 |
| 3.00 | 19 | 25.6895 | 4.87544 | 1.11850 | 23.3396 | 28.0394 | 15.80 |
| Total | 40 | 26.5925 | 4.80125 | .75914 | 25.0570 | 28.1280 | 15.80 |

Descriptives

hep2

| | Maximum |
|-------|---------|
| 1.00 | 34.20 |
| 2.00 | 36.30 |
| 3.00 | 36.00 |
| Total | 36.30 |

ANOVA

hep2

| | Sum of Squares | df | Mean Square | F | Sig. |
|----------------|----------------|----|-------------|------|------|
| Between Groups | 29.838 | 2 | 14.919 | .635 | .536 |
| Within Groups | 869.190 | 37 | 23.492 | | |
| Total | 899.028 | 39 | | | |

Post Hoc Tests

Multiple Comparisons

Dependent Variable: hep2

| | (I) Usia_cat | (J) Usia_cat | Mean Difference (I-J) | | Sig. | 95% Confidence Interval Lower Bound |
|------------|--------------|--------------|-----------------------|---------|-------|-------------------------------------|
| | | | Std. Error | | | |
| LSD | 1.00 | 2.00 | .26429 | 2.24364 | .907 | -4.2818 |
| | | 3.00 | 1.89624 | 2.14298 | .382 | -2.4458 |
| | 2.00 | 1.00 | -.26429 | 2.24364 | .907 | -4.8103 |
| | | 3.00 | 1.63195 | 1.70715 | .345 | -1.8271 |
| | 3.00 | 1.00 | -1.89624 | 2.14298 | .382 | -6.2383 |
| | | 2.00 | -1.63195 | 1.70715 | .345 | -5.0910 |
| Bonferroni | 1.00 | 2.00 | .26429 | 2.24364 | 1.000 | -5.3622 |
| | | 3.00 | 1.89624 | 2.14298 | 1.000 | -3.4778 |
| | 2.00 | 1.00 | -.26429 | 2.24364 | 1.000 | -5.8907 |
| | | 3.00 | 1.63195 | 1.70715 | 1.000 | -2.6491 |
| | 3.00 | 1.00 | -1.89624 | 2.14298 | 1.000 | -7.2703 |
| | | 2.00 | -1.63195 | 1.70715 | 1.000 | -5.9130 |

Multiple Comparisons

Dependent Variable: hep2

| | (I) Usia_cat | (J) Usia_cat | 95% Confidence Interval Upper Bound |
|------------|--------------|--------------|--|
| LSD | 1.00 | 2.00 | 4.8103 |
| | | 3.00 | 6.2383 |
| | 2.00 | 1.00 | 4.2818 |
| | | 3.00 | 5.0910 |
| | 3.00 | 1.00 | 2.4458 |
| | | 2.00 | 1.8271 |
| Bonferroni | 1.00 | 2.00 | 5.8907 |
| | | 3.00 | 7.2703 |
| | 2.00 | 1.00 | 5.3622 |
| | | 3.00 | 5.9130 |
| | 3.00 | 1.00 | 3.4778 |
| | | 2.00 | 2.6491 |

NPar Tests

Kruskal-Wallis Test

| Ranks | | | |
|--------|----------|----|-----------|
| | Usia_cat | N | Mean Rank |
| vitd | 1.00 | 7 | 20.57 |
| | 2.00 | 14 | 20.36 |
| | 3.00 | 19 | 20.58 |
| | Total | 40 | |
| GFRNEW | 1.00 | 7 | 19.36 |
| | 2.00 | 14 | 21.07 |
| | 3.00 | 19 | 20.50 |
| | Total | 40 | |

Test Statistics^{a,b}

| | vitd | GFRNEW |
|-------------|------|--------|
| Chi-Square | .003 | .100 |
| df | 2 | 2 |
| Asymp. Sig. | .998 | .951 |

a. Kruskal Wallis Test

b. Grouping Variable: Usia_cat

3. Perbandingan Kadar Hepcidin, Vitamin D, dan GFR berdasarkan Status Gizi pada anak dengan PGK

Descriptives

| SG1 | | Statistic | Std. Error |
|------|------|----------------------------------|-------------|
| hep2 | 1.00 | Mean | 26.5429 |
| | | 95% Confidence Interval for Mean | Lower Bound |
| | | | 20.5331 |
| | | | Upper Bound |
| | | 5% Trimmed Mean | 26.7921 |
| | | Median | 26.0000 |
| | | Variance | 42.226 |
| | | Std. Deviation | 6.49817 |
| | | Minimum | 15.80 |
| | | Maximum | 32.80 |
| | | Range | 17.00 |
| | | Interquartile Range | 9.70 |
| | | Skewness | -.543 .794 |
| | | Kurtosis | -.725 1.587 |
| 2.00 | 2.00 | Mean | 26.1960 |
| | | 95% Confidence Interval for Mean | Lower Bound |
| | | | 24.2825 |
| | | | Upper Bound |
| | | 5% Trimmed Mean | 26.0944 |
| | | Median | 25.8000 |
| | | Variance | 21.489 |
| | | Std. Deviation | 4.63559 |
| | | Minimum | 18.50 |
| | | Maximum | 36.00 |
| | | Range | 17.50 |
| | | Interquartile Range | 7.65 |
| | | Skewness | .253 .464 |
| 3.00 | 3.00 | Kurtosis | -.582 .902 |
| | | Mean | 27.3600 |
| | | 95% Confidence Interval for Mean | Lower Bound |
| | | | 24.4738 |
| | | | Upper Bound |
| | | 5% Trimmed Mean | 27.3833 |
| | | Median | 27.5000 |
| | | Variance | 5.403 |
| | | Std. Deviation | 2.32444 |
| | | Minimum | 24.00 |
| | | Maximum | 30.30 |
| | | Range | 6.30 |
| | | Interquartile Range | 4.05 |
| 4.00 | 4.00 | Skewness | -.393 .913 |
| | | Kurtosis | .721 2.000 |
| | | Mean | 28.7333 |
| | | 95% Confidence Interval for | Lower Bound |
| | | | 12.2848 |

| | | | | | |
|--------|------|----------------------------------|-------------|----------|----------|
| | | Mean | Upper Bound | 45.1819 | |
| | | 5% Trimmed Mean | | . | |
| | | Median | | 25.9000 | |
| | | Variance | | 43.843 | |
| | | Std. Deviation | | 6.62143 | |
| | | Minimum | | 24.00 | |
| | | Maximum | | 36.30 | |
| | | Range | | 12.30 | |
| | | Interquartile Range | | . | |
| | | Skewness | | 1.573 | 1.225 |
| | | Kurtosis | | . | . |
| GFRNEW | 1.00 | Mean | | 87.2714 | 17.23895 |
| | | 95% Confidence Interval for Mean | Lower Bound | 45.0892 | |
| | | | Upper Bound | 129.4536 | |
| | | 5% Trimmed Mean | | 87.5127 | |
| | | Median | | 94.0000 | |
| | | Variance | | 2080.269 | |
| | | Std. Deviation | | 45.60997 | |
| | | Minimum | | 9.20 | |
| | | Maximum | | 161.00 | |
| | | Range | | 151.80 | |
| | | Interquartile Range | | 38.00 | |
| | | Skewness | | -.183 | .794 |
| | | Kurtosis | | 1.823 | 1.587 |
| | 2.00 | Mean | | 104.6280 | 19.70396 |
| | | 95% Confidence Interval for Mean | Lower Bound | 63.9610 | |
| | | | Upper Bound | 145.2950 | |
| | | 5% Trimmed Mean | | 96.2533 | |
| | | Median | | 93.4000 | |
| | | Variance | | 9706.153 | |
| | | Std. Deviation | | 98.51981 | |
| | | Minimum | | 3.00 | |
| | | Maximum | | 374.00 | |
| | | Range | | 371.00 | |
| | | Interquartile Range | | 155.90 | |
| | | Skewness | | 1.015 | .464 |
| | | Kurtosis | | .849 | .902 |
| | 3.00 | Mean | | 73.4000 | 28.16665 |
| | | 95% Confidence Interval for Mean | Lower Bound | -4.8031 | |
| | | | Upper Bound | 151.6031 | |
| | | 5% Trimmed Mean | | 73.4444 | |
| | | Median | | 77.0000 | |
| | | Variance | | 3966.800 | |
| | | Std. Deviation | | 62.98254 | |
| | | Minimum | | 3.00 | |

| | | | | |
|------|--|----------------------------------|-------------|-----------|
| | | Maximum | 143.00 | |
| | | Range | 140.00 | |
| | | Interquartile Range | 125.00 | |
| | | Skewness | -.062 | .913 |
| | | Kurtosis | -2.725 | 2.000 |
| 4.00 | | Mean | 61.6667 | 54.66972 |
| | | 95% Confidence Interval for Mean | Lower Bound | -173.5581 |
| | | | Upper Bound | 296.8915 |
| | | 5% Trimmed Mean | | . |
| | | Median | 8.0000 | |
| | | Variance | 8966.333 | |
| | | Std. Deviation | 94.69072 | |
| | | Minimum | 6.00 | |
| | | Maximum | 171.00 | |
| | | Range | 165.00 | |
| vitd | | Interquartile Range | | . |
| | | Skewness | 1.731 | 1.225 |
| | | Kurtosis | | . |
| | | Mean | 25.4714 | 7.78266 |
| | | 95% Confidence Interval for Mean | Lower Bound | 6.4279 |
| | | | Upper Bound | 44.5149 |
| | | 5% Trimmed Mean | 24.3016 | |
| | | Median | 14.7000 | |
| | | Variance | 423.989 | |
| | | Std. Deviation | 20.59099 | |
| 2.00 | | Minimum | 6.90 | |
| | | Maximum | 65.10 | |
| | | Range | 58.20 | |
| | | Interquartile Range | 28.00 | |
| | | Skewness | 1.434 | .794 |
| | | Kurtosis | 1.584 | 1.587 |
| | | Mean | 20.4504 | 2.39458 |
| | | 95% Confidence Interval for Mean | Lower Bound | 15.5082 |
| | | | Upper Bound | 25.3926 |
| | | 5% Trimmed Mean | 19.2633 | |
| 3.00 | | Median | 17.3000 | |
| | | Variance | 143.350 | |
| | | Std. Deviation | 11.97288 | |
| | | Minimum | 5.26 | |
| | | Maximum | 60.00 | |
| | | Range | 54.74 | |
| | | Interquartile Range | 6.05 | |
| | | Skewness | 1.997 | .464 |
| | | Kurtosis | 4.242 | .902 |
| | | Mean | 16.0000 | 1.66223 |
| | | 95% Confidence Interval for | Lower Bound | 11.3849 |

| | | | | |
|------|----------------------------------|-------------|----------|---------|
| | Mean | Upper Bound | 20.6151 | |
| | 5% Trimmed Mean | | 15.7556 | |
| | Median | | 14.5000 | |
| | Variance | | 13.815 | |
| | Std. Deviation | | 3.71685 | |
| | Minimum | | 13.80 | |
| | Maximum | | 22.60 | |
| | Range | | 8.80 | |
| | Interquartile Range | | 4.85 | |
| | Skewness | | 2.155 | .913 |
| | Kurtosis | | 4.706 | 2.000 |
| 4.00 | Mean | | 19.3667 | 7.50674 |
| | 95% Confidence Interval for Mean | Lower Bound | -12.9322 | |
| | | Upper Bound | 51.6656 | |
| | 5% Trimmed Mean | | . | |
| | Median | | 19.1000 | |
| | Variance | | 169.053 | |
| | Std. Deviation | | 13.00205 | |
| | Minimum | | 6.50 | |
| | Maximum | | 32.50 | |
| | Range | | 26.00 | |
| | Interquartile Range | | . | |
| | Skewness | | .092 | 1.225 |
| | Kurtosis | | . | . |

Tests of Normality

| | SG1 | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
|--------|------|---------------------------------|----|------|--------------|----|------|
| | | Statistic | df | Sig. | Statistic | df | Sig. |
| hep2 | 1.00 | .249 | 7 | .200 | .873 | 7 | .197 |
| | 2.00 | .094 | 25 | .200 | .977 | 25 | .811 |
| | 3.00 | .172 | 5 | .200 | .988 | 5 | .974 |
| | 4.00 | .332 | 3 | . | .863 | 3 | .275 |
| GFRNEW | 1.00 | .201 | 7 | .200 | .947 | 7 | .706 |
| | 2.00 | .151 | 25 | .144 | .890 | 25 | .011 |
| | 3.00 | .215 | 5 | .200 | .901 | 5 | .418 |
| | 4.00 | .381 | 3 | . | .759 | 3 | .020 |
| vitd | 1.00 | .271 | 7 | .130 | .843 | 7 | .105 |
| | 2.00 | .292 | 25 | .000 | .757 | 25 | .000 |
| | 3.00 | .406 | 5 | .007 | .666 | 5 | .004 |
| | 4.00 | .177 | 3 | . | 1.000 | 3 | .966 |

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Oneway

Descriptives

hep2

| | N | Mean | Std. Deviation | Std. Error | 95% Confidence Interval for Mean | | Minimum |
|-------|----|---------|----------------|------------|----------------------------------|-------------|---------|
| | | | | | Lower Bound | Upper Bound | |
| 1.00 | 7 | 26.5429 | 6.49817 | 2.45608 | 20.5331 | 32.5527 | 15.80 |
| 2.00 | 25 | 26.1960 | 4.63559 | .92712 | 24.2825 | 28.1095 | 18.50 |
| 3.00 | 5 | 27.3600 | 2.32444 | 1.03952 | 24.4738 | 30.2462 | 24.00 |
| 4.00 | 3 | 28.7333 | 6.62143 | 3.82288 | 12.2848 | 45.1819 | 24.00 |
| Total | 40 | 26.5925 | 4.80125 | .75914 | 25.0570 | 28.1280 | 15.80 |

Descriptives

hep2

| | Maximum |
|-------|---------|
| 1.00 | 32.80 |
| 2.00 | 36.00 |
| 3.00 | 30.30 |
| 4.00 | 36.30 |
| Total | 36.30 |

Test of Homogeneity of Variances

hep2

| Levene Statistic | df1 | df2 | Sig. |
|------------------|-----|-----|------|
| 2.167 | 3 | 36 | .109 |

ANOVA

hep2

| | Sum of Squares | df | Mean Square | F | Sig. |
|----------------|----------------|----|-------------|------|------|
| Between Groups | 20.642 | 3 | 6.881 | .282 | .838 |
| Within Groups | 878.385 | 36 | 24.400 | | |
| Total | 899.028 | 39 | | | |

Post Hoc Tests

Multiple Comparisons

Dependent Variable: hep2

| | (I) SG1 | (J) SG1 | Mean Difference (I-J) | Std. Error | Sig. | 95% Confidence Interval | |
|-----|---------|---------|--------------------------|------------|------|-------------------------|-------------|
| | | | | | | Lower Bound | Upper Bound |
| LSD | 1.00 | 2.00 | .34686 | 2.11226 | .870 | -3.9370 | 4.6307 |
| | | 3.00 | -.81714 | 2.89233 | .779 | -6.6831 | 5.0488 |
| | | 4.00 | -2.19048 | 3.40864 | .525 | -9.1035 | 4.7226 |
| | 2.00 | 1.00 | -.34686 | 2.11226 | .870 | -4.6307 | 3.9370 |
| | | 3.00 | -1.16400 | 2.41990 | .633 | -6.0718 | 3.7438 |
| | | 4.00 | -2.53733 | 3.01814 | .406 | -8.6584 | 3.5837 |
| | 3.00 | 1.00 | .81714 | 2.89233 | .779 | -5.0488 | 6.6831 |
| | | 2.00 | 1.16400 | 2.41990 | .633 | -3.7438 | 6.0718 |
| | | 4.00 | -1.37333 | 3.60737 | .706 | -8.6894 | 5.9428 |

| | | | | | | | |
|------------|------|------|----------|---------|-------|----------|---------|
| | 4.00 | 1.00 | 2.19048 | 3.40864 | .525 | -4.7226 | 9.1035 |
| | | 2.00 | 2.53733 | 3.01814 | .406 | -3.5837 | 8.6584 |
| | | 3.00 | 1.37333 | 3.60737 | .706 | -5.9428 | 8.6894 |
| Bonferroni | 1.00 | 2.00 | .34686 | 2.11226 | 1.000 | -5.5505 | 6.2442 |
| | | 3.00 | -.81714 | 2.89233 | 1.000 | -8.8924 | 7.2582 |
| | | 4.00 | -2.19048 | 3.40864 | 1.000 | -11.7073 | 7.3264 |
| | 2.00 | 1.00 | -.34686 | 2.11226 | 1.000 | -6.2442 | 5.5505 |
| | | 3.00 | -1.16400 | 2.41990 | 1.000 | -7.9203 | 5.5923 |
| | | 4.00 | -2.53733 | 3.01814 | 1.000 | -10.9639 | 5.8892 |
| | 3.00 | 1.00 | .81714 | 2.89233 | 1.000 | -7.2582 | 8.8924 |
| | | 2.00 | 1.16400 | 2.41990 | 1.000 | -5.5923 | 7.9203 |
| | | 4.00 | -1.37333 | 3.60737 | 1.000 | -11.4450 | 8.6983 |
| | 4.00 | 1.00 | 2.19048 | 3.40864 | 1.000 | -7.3264 | 11.7073 |
| | | 2.00 | 2.53733 | 3.01814 | 1.000 | -5.8892 | 10.9639 |
| | | 3.00 | 1.37333 | 3.60737 | 1.000 | -8.6983 | 11.4450 |

NPar Tests

Kruskal-Wallis Test

Ranks

| | SG1 | N | Mean Rank |
|--------|-------|----|-----------|
| vitd | 1.00 | 7 | 21.50 |
| | 2.00 | 25 | 20.94 |
| | 3.00 | 5 | 16.80 |
| | 4.00 | 3 | 20.67 |
| | Total | 40 | |
| GFRNEW | 1.00 | 7 | 21.29 |
| | 2.00 | 25 | 21.32 |
| | 3.00 | 5 | 18.10 |
| | 4.00 | 3 | 15.83 |
| | Total | 40 | |

Test Statistics^{a,b}

| | vitd | GFRNEW |
|-------------|------|--------|
| Chi-Square | .588 | .844 |
| df | 3 | 3 |
| Asymp. Sig. | .899 | .839 |

a. Kruskal Wallis Test

b. Grouping Variable: SG1

4. Perbandingan Rerata Kadar Hepcidin dan GFR berdasarkan kadar Vitamin D pada anak dengan PGK

Descriptives

| vit_cat_3 | | | Statistic | Std. Error |
|-----------|------|----------------------------------|-------------|--------------|
| hep2 | 1.00 | Mean | 28.8500 | .68808 |
| | | 95% Confidence Interval for Mean | Lower Bound | 27.4382 |
| | | | Upper Bound | 30.2618 |
| | | 5% Trimmed Mean | | 28.7937 |
| | | Median | | 28.4000 |
| | | Variance | | 13.257 |
| | | Std. Deviation | | 3.64097 |
| | | Minimum | | 21.90 |
| | | Maximum | | 36.30 |
| | | Range | | 14.40 |
| | | Interquartile Range | | 5.48 |
| | | Skewness | | .336 .441 |
| | | Kurtosis | | -.421 .858 |
| | 2.00 | Mean | 22.5200 | .59279 |
| | | 95% Confidence Interval for Mean | Lower Bound | 20.8742 |
| | | | Upper Bound | 24.1658 |
| | | 5% Trimmed Mean | | 22.5333 |
| | | Median | | 23.0000 |
| | | Variance | | 1.757 |
| | | Std. Deviation | | 1.32552 |
| | | Minimum | | 20.80 |
| | | Maximum | | 24.00 |
| | | Range | | 3.20 |
| | | Interquartile Range | | 2.50 |
| | | Skewness | | -.416 .913 |
| | | Kurtosis | | -1.904 2.000 |
| | 3.00 | Mean | 20.4714 | 1.04852 |
| | | 95% Confidence Interval for Mean | Lower Bound | 17.9058 |
| | | | Upper Bound | 23.0371 |
| | | 5% Trimmed Mean | | 20.5849 |
| | | Median | | 21.9000 |
| | | Variance | | 7.696 |
| | | Std. Deviation | | 2.77412 |
| | | Minimum | | 15.80 |
| | | Maximum | | 23.10 |
| | | Range | | 7.30 |
| | | Interquartile Range | | 4.50 |
| | | Skewness | | -.786 .794 |
| | | Kurtosis | | -.694 1.587 |
| GFRNEW | 1.00 | Mean | 77.5750 | 13.34454 |
| | | 95% Confidence Interval for | Lower Bound | 50.1943 |

| | | | | |
|------|----------------------------------|-------------|-----------|----------|
| | Mean | Upper Bound | 104.9557 | |
| | 5% Trimmed Mean | | 71.7897 | |
| | Median | | 74.0000 | |
| | Variance | | 4986.146 | |
| | Std. Deviation | | 70.61265 | |
| | Minimum | | 3.00 | |
| | Maximum | | 288.00 | |
| | Range | | 285.00 | |
| | Interquartile Range | | 120.20 | |
| | Skewness | | .975 | .441 |
| | Kurtosis | | 1.190 | .858 |
| 2.00 | Mean | Lower Bound | 101.1000 | 38.92249 |
| | 95% Confidence Interval for Mean | Upper Bound | -6.9661 | |
| | 5% Trimmed Mean | | 209.1661 | |
| | Median | | 102.1944 | |
| | Variance | | 154.0000 | |
| | Std. Deviation | | 7574.800 | |
| | Minimum | | 87.03333 | |
| | Maximum | | 4.50 | |
| | Range | | 178.00 | |
| | Interquartile Range | | 173.50 | |
| | Skewness | | 163.25 | .913 |
| | Kurtosis | | -.563 | 2.000 |
| 3.00 | Mean | Lower Bound | 157.2857 | 45.47669 |
| | 95% Confidence Interval for Mean | Upper Bound | 46.0083 | |
| | 5% Trimmed Mean | | 268.5632 | |
| | Median | | 152.8730 | |
| | Variance | | 140.0000 | |
| | Std. Deviation | | 14476.905 | |
| | Minimum | | 120.32001 | |
| | Maximum | | 20.00 | |
| | Range | | 374.00 | |
| | Interquartile Range | | 354.00 | |
| | Skewness | | 159.00 | .794 |
| | Kurtosis | | .906 | 1.587 |

Tests of Normality

| | vit_cat_3 | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
|--------|-----------|---------------------------------|----|------|--------------|----|------|
| | | Statistic | df | Sig. | Statistic | df | Sig. |
| hep2 | 1.00 | .099 | 28 | .200 | .975 | 28 | .726 |
| | 2.00 | .241 | 5 | .200 | .933 | 5 | .620 |
| | 3.00 | .268 | 7 | .138 | .877 | 7 | .214 |
| GFRNEW | 1.00 | .162 | 28 | .059 | .887 | 28 | .006 |
| | 2.00 | .328 | 5 | .083 | .765 | 5 | .041 |
| | 3.00 | .179 | 7 | .200 | .938 | 7 | .619 |

*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction

NPar Tests

Kruskal-Wallis Test

| Ranks | | | |
|--------|-----------|----|-----------|
| | vit_cat_3 | N | Mean Rank |
| hep2 | 1.00 | 28 | 26.25 |
| | 2.00 | 5 | 8.80 |
| | 3.00 | 7 | 5.86 |
| | Total | 40 | |
| GFRNEW | 1.00 | 28 | 18.36 |
| | 2.00 | 5 | 22.50 |
| | 3.00 | 7 | 27.64 |
| | Total | 40 | |

Test Statistics^{a,b}

| | hep2 | GFRNEW |
|-------------|--------|--------|
| Chi-Square | 22.773 | 3.701 |
| df | 2 | 2 |
| Asymp. Sig. | .000 | .157 |

a. Kruskal Wallis Test
b. Grouping Variable: vit_cat_3

T-Test

| Group Statistics | | | | | |
|------------------|------------|----|---------|----------------|-----------------|
| | vit_D_3_12 | N | Mean | Std. Deviation | Std. Error Mean |
| hep_12 | 1.00 | 28 | 28.8500 | 3.64097 | .68808 |
| | 2.00 | 5 | 22.5200 | 1.32552 | .59279 |

Independent Samples Test

| | | Levene's Test for Equality of Variances | | t-test for Equality of Means | |
|--------|-----------------------------|---|------|------------------------------|--------|
| | | F | Sig. | t | df |
| hep_12 | Equal variances assumed | 4.178 | .050 | 3.800 | 31 |
| | Equal variances not assumed | | | 6.970 | 17.369 |

Independent Samples Test

t-test for Equality of Means

| | hep_12 | Sig. (2-tailed) | Mean Difference | Std. Error Difference | 95% Confidence Interval of the Difference |
|--------|-----------------------------|-----------------|-----------------|-----------------------|---|
| | | | | | Lower |
| hep_12 | Equal variances assumed | .001 | 6.33000 | 1.66584 | 2.93249 |
| hep_12 | Equal variances not assumed | .000 | 6.33000 | .90821 | 4.41693 |

Independent Samples Test

t-test for Equality of Means
95% Confidence Interval of the
Difference
Upper

| | hep_12 | Equal variances assumed | 9.72751 |
|--|--------|-----------------------------|---------|
| | | Equal variances not assumed | 8.24307 |

T-Test

Group Statistics

| | vit_D_3_13 | N | Mean | Std. Deviation | Std. Error Mean |
|--------|------------|----|---------|----------------|-----------------|
| hep_13 | 1.00 | 28 | 28.8500 | 3.64097 | .68808 |
| | 2.00 | 7 | 20.4714 | 2.77412 | 1.04852 |

Independent Samples Test

Levene's Test for Equality of
Variances

t-test for Equality of
Means

| | hep_13 | F | Sig. | t | df |
|--------|-----------------------------|------|------|-------|--------|
| | | .619 | .437 | 5.666 | 33 |
| hep_13 | Equal variances assumed | | | 6.681 | 11.794 |
| hep_13 | Equal variances not assumed | | | | |

Independent Samples Test

t-test for Equality of Means

| | hep_13 | Sig. (2-tailed) | Mean Difference | Std. Error Difference | 95% Confidence Interval of the Difference |
|--------|-----------------------------|-----------------|-----------------|-----------------------|---|
| | | | | | Lower |
| hep_13 | Equal variances assumed | .000 | 8.37857 | 1.47875 | 5.37003 |
| hep_13 | Equal variances not assumed | .000 | 8.37857 | 1.25413 | 5.64077 |

Independent Samples Test

t-test for Equality of Means
95% Confidence Interval of the
Difference
Upper

| | hep_13 | Equal variances assumed | 11.38712 |
|--|--------|-----------------------------|----------|
| | | Equal variances not assumed | 11.11637 |

T-Test

| Group Statistics | | | | | |
|------------------|------------|---|---------|----------------|-----------------|
| | vit_D_3_23 | N | Mean | Std. Deviation | Std. Error Mean |
| hep_23 | 1.00 | 5 | 22.5200 | 1.32552 | .59279 |
| | 2.00 | 7 | 20.4714 | 2.77412 | 1.04852 |

| Independent Samples Test | | | | | |
|--------------------------|-----------------------------|--|------------------------------|------|-------|
| | | | t-test for Equality of Means | | |
| | | | F | Sig. | t |
| hep_23 | Equal variances assumed | | 5.283 | .044 | 1.517 |
| | Equal variances not assumed | | | | 1.701 |
| | | | | | 9.060 |

| Independent Samples Test | | | | | |
|--------------------------|-----------------------------|--|------------------------------|-----------------|-----------------------|
| | | | t-test for Equality of Means | | |
| | | | Sig. (2-tailed) | Mean Difference | Std. Error Difference |
| hep_23 | Equal variances assumed | | .160 | 2.04857 | 1.35058 |
| | Equal variances not assumed | | .123 | 2.04857 | 1.20449 |
| | | | | | -.96072 |
| | | | | | -.67341 |

| Independent Samples Test | | | | | |
|--------------------------|-----------------------------|--|---|-------|---------|
| | | | t-test for Equality of Means | | |
| | | | 95% Confidence Interval of the Difference | Upper | Lower |
| hep_23 | Equal variances assumed | | | | 5.05786 |
| | Equal variances not assumed | | | | 4.77055 |

5. Korelasi kadar Hepcidin, Vitamin D dan GFR pada anak dengan PGK

| Tests of Normality | | | | | | |
|--------------------|---------------------------------|----|------|--------------|----|------|
| | Kolmogorov-Smirnov ^a | | | Shapiro-Wilk | | |
| | Statistic | df | Sig. | Statistic | df | Sig. |
| hep2 | .073 | 40 | .200 | .989 | 40 | .966 |
| vitd | .250 | 40 | .000 | .768 | 40 | .000 |
| GFRNEW | .143 | 40 | .037 | .889 | 40 | .001 |

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Nonparametric Correlations

Correlations

| | | hep | vitd | GFR |
|----------------|------|---|-----------------------|-----------------------|
| Spearman's rho | hep | Correlation Coefficient Sig. (2-tailed) N | 1.000 .000 40 | -.856** .347 40 |
| | vitd | Correlation Coefficient Sig. (2-tailed) N | -.856** .000 40 | 1.000 .854 40 |
| | | Correlation Coefficient Sig. (2-tailed) N | -.153 .347 40 | 1.000 .854 40 |

**. Correlation is significant at the 0.01 level (2-tailed).

LAMPIRAN 5

| No | Nama pasien | RM | JK | Usia | BB | TB | GIZI | Diagnosa | Hepci din | VIT D | GFR | Stage PGK |
|----|-------------|--------|----|---------------|------|-----|---------------------|--|-----------|-------|------|-----------|
| 1 | FA | 931126 | P | 10 thn 4 bln | 43.1 | 153 | Gizi baik | CKD III + Sindrom nefrotik | 25.7 | 15.6 | 40 | Stage 3b |
| 2 | FE | 922922 | L | 16 thn | 46 | 164 | Gizi baik | CKD I + Sindrom nefrotik | 27.5 | 14.1 | 143 | Stage 1 |
| 3 | ZQ | 933397 | P | 1 thn | 9 | 80 | Gizi baik | CKD I + Sindrom Nefrotik | 32.7 | 11.8 | 107 | Stage 1 |
| 4 | RP | 866128 | L | 6 thn 3 bln | 18 | 110 | Gizi baik | CKD I + Sindrom nefrotik | 18.5 | 38.8 | 140 | Stage 1 |
| 5 | AA | 921041 | P | 4thn 6bl | 14 | 97 | Gizi baik | CKD I + Sindrom nefrotik | 27.6 | 11.7 | 177 | Stage 1 |
| 6 | AH | 924830 | L | 5 thn 3bln | 18 | 105 | Gizi baik | CKD I + Sindrom nefrotik | 26.8 | 14.4 | 288 | Stage 1 |
| 7 | ZV | 892094 | P | 2 tahun | 10.5 | 78 | Gizi baik | CKD I + Sindrom nefrotik | 20.8 | 20.7 | 178 | Stage 1 |
| 8 | RS | 675151 | L | 9 thn 6 bln | 20 | 114 | Gizi baik | CKD I + Sindrom nefrotik | 23.1 | 22.3 | 194 | Stage 1 |
| 9 | NH | 899899 | P | 8 thn | 20 | 118 | Gizi baik | CKD I + Sindrom nefrotik | 23.3 | 19.6 | 154 | Stage 1 |
| 10 | MI | 925316 | L | 9 thn 5 bln | 29 | 129 | Overweight | CKD I + Sindrom nefrotik | 23 | 25.5 | 161 | Stage 1 |
| 11 | ZF | 521315 | L | 10 thn 11 bln | 28 | 130 | Gizi baik | CKD I + Sindrom nefrotik | 27 | 14.2 | 140 | Stage 1 |
| 12 | MJ | 861940 | L | 3 thn 8 bln | 15 | 95 | Gizi baik | CKD I + Sindrom nefrotik relaps jarang | 28.4 | 14.5 | 130 | Stage 1 |
| 13 | HK | 910288 | L | 16 thn | 34 | 139 | Gizi baik | CKD I + Sindrom nefrotik relaps jarang | 18.9 | 39.8 | 374 | Stage 1 |
| 14 | AQ | 930704 | L | 2 thn 5 bln | 18 | 93 | Obesitas | CKD I +SNRS | 24 | 22.6 | 127 | Stage 1 |
| 15 | AT | 926874 | L | 10 thn 9 bln | 30 | 125 | Obesitas | CKD I + SNRS | 36.3 | 6.5 | 171 | Stage 1 |
| 16 | NT | 931736 | P | 13 thn 4 bln | 26 | 132 | Gizi baik | CKD I + SNRS | 34.2 | 13.5 | 103 | Stage 1 |
| 17 | GV | 877426 | L | 3 thn | 13 | 83 | Beresiko gizi lebih | CKD II+SNRS HT grade 2 | 23 | 65.1 | 76 | Stage 2 |
| 18 | RA | 821644 | P | 13 thn 8 bln | 52 | 155 | overweight | CKD I + SNRS +Diffuse global Glomerulosclerosis | 32.5 | 6.9 | 94.7 | Stage 1 |
| 19 | FT | 910276 | P | 15 thn 10 bln | 36 | 150 | Gizi kurang | CKD I + lupus Nefritis | 22.1 | 60 | 228 | Stage 1 |
| 20 | AN | 879075 | L | 17 thn 11 bln | 38 | 153 | Gizi kurang | CKD III + Lupus nefritis +HT gr 1 | 31.1 | 12.8 | 56.8 | Stage 3a |
| 21 | GA | 926602 | P | 5 thn 6 bln | 16 | 107 | Gizi kurang | CKD I + lupus Nefritis + SLE | 36 | 5.26 | 93.4 | Stage 1 |
| 22 | SM | 930646 | P | 14 thn 5 bln | 45 | 150 | Gizi kurang | CKD 5 + lupus nefritis + SLE | 24.1 | 18.9 | 4.8 | Stage 5 |
| 23 | RS | 754182 | P | 13 thn | 49.5 | 152 | overweight | CKD I + Lupus Nefritis | 25.8 | 14.4 | 139 | Stage 1 |
| 24 | ZZ | 920812 | P | 17 thn 3 bln | 47 | 153 | overweight | Lupus nefritis | 28.4 | 13.8 | 77 | Stage 2 |
| 25 | NB | 843280 | L | 5 thn 3 bln | 20 | 110 | Gizi baik | CKD IV + PNC bilateral | 21.9 | 40.3 | 20 | Stage 4 |
| 26 | MD | 921066 | L | 11 thn 8 bln | 25 | 130 | Gizi baik | CKD V + PNC bilateral | 25.4 | 19.2 | 4 | Stage 4 |
| 27 | RFI | 857882 | L | 7 th 7 bln | 15 | 105 | Gizi kurang | CKD V + PNC bilateral | 30.3 | 15 | 3 | Stage 5 |
| 28 | NQ | 922538 | P | 10 thn 8 bln | 24 | 122 | Gizi baik | CKD V + RPGN | 21.9 | 18.9 | 8 | Stage 5 |
| 29 | RA | 928312 | P | 14 thn 4 bln | 34 | 146 | Gizi kurang | CKD V + PNC bilateral | 32.8 | 14.5 | 9.2 | Stage 5 |
| 30 | MR | 925627 | L | 15 thn 9 bln | 36 | 148 | Gizi baik | CKD V + PNC bilateral | 21.5 | 20 | 4.5 | Stage 5 |
| 31 | DK | 816136 | L | 16 thn 10 bln | 43 | 145 | overweight | CKD IV + Glomerulonefritis +hidronefrosis bilateral | 26.6 | 14.5 | 17 | Stage 4 |
| 32 | MR | 904266 | L | 17 thn | 42 | 150 | Gizi baik | CKD III + SNRS | 29 | 18.3 | 46 | Stage 3a |
| 33 | RZ | 933391 | L | 15 thn | 61 | 171 | Gizi baik | CKD V + PNC bilateral | 29.7 | 15.7 | 3 | Stage 5 |
| 34 | AM | 922868 | L | 17 thn | 51.5 | 165 | Gizi baik | CKD V + PNC bilateral | 24 | 32.5 | 8 | Stage 5 |
| 35 | IM | 930342 | P | 16 thn 3 bln | 38 | 152 | Gizi baik | CKD V + PNC bilateral | 31 | 15.1 | 9 | Stage 5 |
| 36 | ZR | 844416 | P | 16 thn 4 bln | 39 | 153 | Gizi baik | CKD V + PNC bilateral | 31.5 | 10 | 10.2 | Stage 5 |
| 37 | NS | 918288 | P | 14 thn 11 bln | 35.3 | 147 | Gizi baik | CKD V + Membanoo progressive glomerulonephritis | 25.9 | 19.1 | 6 | Stage 5 |
| 38 | NA | 933642 | P | 12 thn 1 bln | 20 | 128 | Gizi kurang | CKD II + Glomerulonefritis | 15.8 | 39.8 | 69 | Stage 2 |
| 39 | ES | 920996 | P | 7 bln | 7.2 | 65 | Gizi baik | CKD I +Hidronefrosis gr 4 ec left ureterovesica junction obstruction | 26 | 14.7 | 94 | Stage 1 |
| 40 | VS | 748904 | P | 11 thn 1 bln | 31.5 | 140 | Gizi baik | CKD II + Multiple kista ginjal | 29.6 | 17.3 | 71 | Stage 2 |